We have previously observed that the combination immunotherapy termed AIPV (short for anti-tumor-associated-antigen [anti-TAA] Ab, extended-half-life interleukin-2, anti-PD-1 Ab, and amphiphile vaccine) causes robust tumor rejection and immunological memory in several mouse models resulting in successful rejection of a secondary subcutaneous rechallenge. Here, IL2 is linked to neoplasm.